Shots:
- Samsung Biologics’ US subsidiary entered a definitive agreement to acquire 100% of Human Genome Sciences from GSK, securing its first US based manufacturing site in Rockville, Maryland
- As per the deal terms, Samsung Biologics will acquire the Rockville assets for $280M, with closing expected by end of Q1’26, while retaining 500+ employees to ensure continuity
- The cGMP facility includes two plants with 60,000L drug substance capacity, supporting both clinical and commercial production from small to large scale; Samsung plans additional investments to expand capacity and upgrade technology
Ref: Samsung Biologics | Image: Samsung Biologics | Press Release
Related News: GSK Reports the FDA Approval of Exdensur (Depemokimab-ulaa) for Asthma with Eosinophilic Phenotype
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
